Understanding how a new peptide drug helps reduce inflammation in type 1 diabetes
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes
This study is looking at a new drug called OPT101 that aims to help people with type 1 diabetes by reducing inflammation and possibly improving how their insulin-producing cells work, and if you're interested, you might get a chance to join future trials if you qualify!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11015052 on NIH RePORTER |
What this research studies
This research investigates a novel peptide drug, OPT101, which targets inflammation caused by CD40 in patients with type 1 diabetes. The study aims to understand how this drug works to potentially restore beta cell function, reduce insulin needs, and lower systemic inflammation markers. By conducting mechanism of action studies, the research will build on promising pre-clinical results that showed significant improvements in diabetic mice and initial veterinary trials. Patients may have the opportunity to participate in upcoming clinical trials if they meet specific criteria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes who are experiencing challenges in managing their blood glucose levels.
Not a fit: Patients with type 2 diabetes or those who do not have autoimmune-related diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves blood sugar control and reduces the need for insulin in type 1 diabetes patients.
How similar studies have performed: Previous research has shown promising results with similar approaches in animal models, but this specific peptide drug is being tested in humans for the first time.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Wagner, David H. — University of Colorado Denver
- Study coordinator: Wagner, David H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.